PMID- 32031980
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20201217
IS  - 2191-0286 (Electronic)
IS  - 0792-6855 (Linking)
VI  - 30
IP  - 6
DP  - 2020 Feb 7
TI  - Decreasing angiogenesis vasa vasorum through Lp-PLA2 and H2O2 inhibition by PSP 
      from Ganoderma lucidum in atherosclerosis: in vivo diabetes mellitus type 2.
LID - /j/jbcpp.2019.30.issue-6/jbcpp-2019-0349/jbcpp-2019-0349.xml [pii]
LID - 10.1515/jbcpp-2019-0349 [doi]
AB  - Background Type 2 diabetes mellitus (T2DM) is a major risk factor of 
      atherosclerosis. Hyperglycemia in T2DM causes advanced formation of glycation end 
      products (AGE) which leads to oxidative stress and chronic inflammation. 
      Oxidative stress occurs due to increased levels of reactive oxygen species (ROS) 
      such as H2O2. On the other hand, lipoprotein-associated phospholipase (Lp-PLA2) 
      has pro-inflammatory effects, which cause instability of atherosclerosis plaques. 
      This condition causes hypoxemic cells to stimulate HIFalpha induced vasa vasorum 
      angiogenesis. This study aims to understand the potential of PSP as an 
      anti-angiogenic agent through decreased levels of H2O2 and Lp-PLA2 leading to the 
      decline of vasa vasorum angiogenesis in diabetic rat model. In addition, this 
      study also measured the lipid profile of diabetic rat model in relation to vasa 
      vasorum angiogenesis. Methods True laboratory experiment with randomized 
      post-test control of group design using 25 wistar rats (Rattus norvegicus) were 
      divided into five groups; one normal group and four group with High Fat Diet 
      (HFD) and low dose streptozotocin (30 mg/kgBW) injection sc, treated with placebo 
      and three various doses of PSP 50, 150, 300 mg/kgBW. Results ANOVA test (p < 
      0.05) shows that there is a significant influence of polysaccharide peptide (PSP) 
      feeding on the decreased amount of vasa vasorum angiogenesis (p = 0.00), lipid 
      profile (cholesterol total and triglyceride; p = 0.01, p = 0.001), and amount of 
      H202 (p = 0.003). The amount of Lp-PLA2 declined to (p = 0.184). This result 
      indicates that PSP prevents inflammation in atherosclerosis. Conclusions PSP of 
      Ganoderma lucidum is an anti-angiogenic agent in T2DM.
FAU - Wihastuti, Titin Andri
AU  - Wihastuti TA
AUID- ORCID: 0000-0001-6476-0541
AD  - Brawijaya University, Department of Biomedical Nursing, Faculty of Medicine, 
      Malang, Indonesia.
FAU - Amiruddin, Reyhan
AU  - Amiruddin R
AD  - Master Program of Biomedical, Faculty of Medicine, Brawijaya University, Malang, 
      Indonesia.
FAU - Cesa, Fibe Yulinda
AU  - Cesa FY
AD  - Master Program of Biomedical, Faculty of Medicine, Brawijaya University, Malang, 
      Indonesia.
FAU - Alkaf, Amalia Istiqamah
AU  - Alkaf AI
AD  - Bachelor Programme, Faculty of Medicine, Brawijaya University, Malang, Indonesia.
FAU - Setiawan, Meddy
AU  - Setiawan M
AD  - Department of Internal Medicine, Faculty of Medicine, University of Muhammadiyah, 
      Malang, Indonesia.
FAU - Heriansyah, Teuku
AU  - Heriansyah T
AD  - Department of Cardiology, Faculty of Medicine, Syiah Kuala University, Aceh, 
      Indonesia, Phone: (+62)8116618282, Fax: (0651)43878.
LA  - eng
PT  - Journal Article
DEP - 20200207
PL  - Germany
TA  - J Basic Clin Physiol Pharmacol
JT  - Journal of basic and clinical physiology and pharmacology
JID - 9101750
RN  - 0 (Plant Extracts)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - EC 3.1.1.47 (1-Alkyl-2-acetylglycerophosphocholine Esterase)
SB  - IM
MH  - 1-Alkyl-2-acetylglycerophosphocholine Esterase/*antagonists & inhibitors
MH  - Animals
MH  - Atherosclerosis/*drug therapy/etiology/pathology
MH  - Diabetes Mellitus, Experimental/*complications
MH  - Hydrogen Peroxide/*antagonists & inhibitors
MH  - Neovascularization, Pathologic/*drug therapy/etiology/pathology
MH  - Plant Extracts/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Reishi/*chemistry
MH  - Vasa Vasorum/*drug effects/pathology
OTO - NOTNLM
OT  - Ganoderma lucidum
OT  - atherosclerosis
OT  - vasa vasorum
EDAT- 2020/02/08 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/02/08 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2019/11/20 00:00 [accepted]
PHST- 2020/02/08 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
PHST- 2020/02/08 06:00 [entrez]
AID - /j/jbcpp.ahead-of-print/jbcpp-2019-0349/jbcpp-2019-0349.xml [pii]
AID - 10.1515/jbcpp-2019-0349 [doi]
PST - epublish
SO  - J Basic Clin Physiol Pharmacol. 2020 Feb 
      7;30(6):/j/jbcpp.2019.30.issue-6/jbcpp-2019-0349/jbcpp-2019-0349.xml. doi: 
      10.1515/jbcpp-2019-0349.